Related Experiment Videos
Epistatic interactions between modifier genes confer strain-specific redundancy for Tgfb1 in developmental
Yang Tang1, Kyeong Sook Lee, HaiTao Yang
1Mt. Zion Cancer Research Institute, University of California, San Francisco, Box 0875, 2340 Sutter Street, Room S231, San Francisco, CA 94143, USA.
Genomics
|December 21, 2004
Summary
Researchers identified two key genetic loci, Tgfbm1 and Tgfbm3, that influence blood vessel development in mice lacking transforming growth factor beta1 (TGFbeta1). These findings may lead to new therapies for angiogenesis-related diseases.
Area of Science:
- Genetics
- Developmental Biology
- Cardiovascular Research
Background:
- Transforming growth factor beta1 (TGFbeta1) plays a crucial role in various biological processes, including angiogenesis.
- Understanding genetic modifiers of TGFbeta1 function is essential for comprehending its in vivo actions and therapeutic responses.
Purpose of the Study:
- To identify genetic loci that modify developmental angiogenesis in mice lacking TGFbeta1.
- To investigate potential epistatic interactions between these modifier loci.
- To explore the therapeutic implications of identified genes in angiogenesis-related diseases.
Main Methods:
- Utilized gene knockout and transgenic mouse models predisposed to complex traits like angiogenesis.
- Employed congenic mouse strains to validate identified genetic loci.
- Performed genetic analysis to identify modifier loci and their interactions.
Main Results:
- Identified Tgfbm1 (chromosome 5) and Tgfbm3 (chromosome 12) as significant loci modifying developmental angiogenesis in Tgfb1-/- mice.
- Validated these loci using congenic mice and demonstrated epistatic interaction between them.
- The Tgfbm3 locus, containing ~22 genes, colocalizes with tumor and atherosclerosis susceptibility loci and is enriched for genes involved in cell growth and morphogenesis.
Conclusions:
- The identified loci, particularly Tgfbm3, offer insights into the genetic regulation of angiogenesis.
- Understanding these modifiers can enhance the prediction of patient response to anti-TGFbeta1 therapies.
- The identified angiogenesis-modifying genes represent potential novel targets for therapeutic interventions in diseases involving aberrant blood vessel formation.